<DOC>
	<DOCNO>NCT00239434</DOCNO>
	<brief_summary>The objective study compare bronchodilator efficacy safety daily dose tiotropium inhalation capsule ( 18 ? g ) Atrovent ? MDI ( 2 puff ipratropium bromide 20 ? g four time daily ) patient chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>A Comparison 18g Tiotropium Inhalation Capsules Once Daily Atrovent Metered Dose Inhaler ( 2 Puffs 20g , 4 Times Daily ) Double-Blind , Double-Dummy , Efficacy Safety Study Adults With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>This randomize , double-blind , double-dummy , parallel group study compare bronchodilator efficacy safety tiotropium inhalation capsule Atrovent ? MDI patient chronic obstructive pulmonary disease ( COPD ) . Following initial screen visit , patient enter 2-week baseline period . Patients successfully complete phase randomize double-blind portion study receive tiotropium daily ( morning ) Atrovent ? four time daily 4 week . Pulmonary function test conduct prior ( i.e . 5 minute ) start therapy Visit 2 ( i.e . randomization visit completion 2-week run-in period ) 30 , 60 , 120 180 minute post-dosing . Pulmonary function test repeated time interval 14 day therapy ( visit 3 ) end therapy . Those patient take theophylline , question last theophylline intake order ensure adherence washout requirement . Vital sign measure conjunction pulmonary function test . Adverse event record throughout entire run-in treatment period . Study Hypothesis : The null hypothesis difference mean response tiotropium Atrovent . The alternative hypothesis difference mean response tiotropium Atrovent . Comparison ( ) : The primary pulmonary function variable FEV1 ( Forced Expiratory Volume one second ) trough FEV1 response end four week treatment period , i.e . visit 4 , primary efficacy endpoint . Trough FEV1 define FEV1 end dose interval ( tiotropium approximately 24 hour post treatment administration ) . On test day ( Visits 3 4 ) measure PFT prior dose . Trough FEV1 response define change baseline trough FEV1 . Baseline FEV1 define FEV1 measure prior first dose morning randomization visit ( Visit 2 ) .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>1 . All patient must diagnosis chronic obstructive pulmonary disease accord follow criterion : Patients must relatively stable airway obstruction FEV1 ? 65 % predict normal FEV1 70 % FVC . Predicted normal value base follow formula . Males : FEV1 pred . ( L ) = height2 ( ) x ( 0.016 x age ( year ) + 1.823 ) Females : FEV1 pred . ( L ) = height2 ( ) x ( 0.012 x age ( year ) + 1.4427 ) 2 . Male female patient 40 year age old . 3 . Patients must smoke history 10 packyears . A packyear defined equivalent smoke one pack cigarettes per day year . 4 . Patients must able perform pulmonary function test require protocol . 5 . Patients must able inhale medication HandiHaler device good technique inhale aerosol administer MDI . 6 . All patient must sign Informed Consent Form prior participation trial i.e. , prior prestudy washout usual pulmonary medication . 1 . Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study . 2 . Patients clinically significant abnormal baseline hematology , blood chemistry urinalysis , abnormality defines disease list exclusion criterion exclude . 3 . All patient SGOT SGPT twice normal range , bilirubin 150 % creatinine 125 % normal range exclude regardless clinical condition . Repeat laboratory evaluation conduct subject . 4 . Patients recent history ( i.e . one year less ) myocardial infarction . 5 . Patients recent history ( i.e . three year less ) heart failure patient cardiac arrhythmia require drug therapy . 6 . Patients regular use daytime oxygen therapy . 7 . Patients know active tuberculosis . 8 . Patients history cancer within last five year . Patients treat basal cell carcinoma allow . 9 . Patients history lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis . 10 . Patients undergone pulmonary resection . 11 . Patients upper respiratory tract infection past 6 week prior Screening Visit ( =Visit 1 ) baseline period 2weeks ( runin period ) . 12 . Patients know hypersensitivity anticholinergic drug , lactose component inhalation capsule delivery system MDI . 13 . Patients know symptomatic prostatic hyperplasia bladder neck obstruction . 14 . Patients know narrowangle glaucoma . 15 . Patients treat cromolyn sodium nedocromil sodium . 16 . Patients treat antihistamine . 17 . Patients use oral corticosteroid medication unstable ( i.e . le 6 week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day . 18 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception ( e.g . oral contraceptive , intrauterine device , diaphragm ) . 19 . Patients history asthma , allergic rhinitis atopy blood total eosinophil count &gt; = 400 per µl ( male ) &gt; = 320 per µl ( female ) . A repeat eosinophil count conduct patient . 20 . Patients history and/or active alcohol drug abuse . 21 . Patients take investigational drug one month six halflives ( whichever great ) prior Screening Visit ( =Visit 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>